Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2020-09-24 Transaction in Own Shar…
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Acquisition ou cession des actions de l'émetteur / Transactions sur actions propres (version détaillée)
Transaction in Own Shares Classification · 98% confidence The document text explicitly states it is an "Information Réglementée – déclaration de transactions sur actions propres" (Regulated Information - declaration of transactions on own shares) made in application of European regulation No 596/2014 (MAR). It details transactions on the company's own shares for a specific period (September 16 to 22, 2020). This content directly corresponds to the definition of reporting personal share transactions by company directors and executives, which in this context, when referring to the company transacting its own shares (share repurchase/issuance), aligns best with the 'Transaction in Own Shares' category (POS). Although it involves insider-like activity reporting (MAR regulation), the subject is the company's own shares, not director's personal dealings (DIRS).
2020-09-24 French
Acquisition ou cession des actions de l'émetteur / Transactions sur actions propres (version détaillée)
Transaction in Own Shares Classification · 99% confidence The document text explicitly states: "Information Réglementée – déclaration de transactions sur actions propres" (Regulated Information - declaration of transactions on own shares) and references European Regulation No 596/2014 (MAR) regarding transactions in own shares for the period of September 10 to 15, 2020. This content directly corresponds to the definition of a report detailing the company buying back or selling its own shares. The appropriate classification code is POS (Transaction in Own Shares).
2020-09-16 French
Acquisition or disposal of the issuer's own shares / Transaction in own shares (detailed version)
Transaction in Own Shares Classification · 99% confidence The document explicitly states it is 'Regulated Information – disclosure of trading in own shares' pursuant to European regulation no 596/2014 (MAR regulation), detailing purchases of its own shares by the issuer (bioMérieux) between specific dates (September 10th to 15th, 2020). This directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS). It is not a general regulatory filing (RNS) because it fits a more specific category.
2020-09-16 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as mandated by French commercial code and AMF regulations. This type of filing, which reports on share capital structure and voting rights, is most closely aligned with general regulatory reporting or specific capital structure updates. Given the options, it is a mandatory regulatory disclosure concerning share capital, but it is not a standard US SEC filing like 10-K or a specific dividend/insider trade report. Since it deals with the total number of shares and voting rights, it relates to the capital structure. However, none of the codes perfectly match a French 'Droits de Vote' filing. The closest fit among the provided definitions that deals with share structure changes or mandatory disclosures not covered elsewhere is 'Share Issue/Capital Change' (SHA) or potentially 'Regulatory Filings' (RNS). Since this is a recurring, mandatory disclosure about the total number of shares and voting rights (which underpins capital structure), and it is not a dividend announcement (DIV) or director dealing (DIRS), SHA is a plausible fit as it relates to the capital base. However, given the specific nature of reporting voting rights under French law, and the lack of a specific code for this, RNS (Regulatory Filings - fallback) is often used for miscellaneous mandatory regulatory reports. Upon review, this specific report (Article L. 233-8 II) is a standard monthly disclosure of share capital and voting rights. While SHA covers capital changes, this is a static monthly count. RNS is the most appropriate fallback for specific, non-US, mandatory regulatory reports that don't fit the other categories. I will classify it as RNS as it is a general regulatory announcement.
2020-09-03 French
Rapports financiers et d'audit semestriels/examens réduits / Modalités de mise à disposition du rapport financier semestriel
Report Publication Announcement Classification · 99% confidence The document is extremely short (727 characters) and its title is "Avis de mise à disposition du rapport financier semestriel 2020" (Notice of availability of the 2020 half-year financial report). The text explicitly states that the half-year financial report is 'mis à la disposition du public' (made available to the public) and can be consulted on the company website. This perfectly matches the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, rather than the report itself (which would be classified as IR if comprehensive).
2020-09-02 French
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Half-Year Financial Report) for bioMérieux SA, covering the period ending June 30, 2020. It contains comprehensive financial statements, including the consolidated income statement, statement of comprehensive income, and balance sheet, along with detailed notes and management commentary. As it is a comprehensive financial report for a period shorter than a full fiscal year, it fits the definition of an Interim/Quarterly Report (IR). H2 2020
2020-09-02 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.